Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9732058 | ASTRAZENECA | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
Jul, 2032
(9 years from now) | |
US11524951 | ASTRAZENECA | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
Jul, 2032
(9 years from now) | |
US8946235 | ASTRAZENECA | 2-(2,4,5-substituted-anilino) pyrimidine compounds |
Aug, 2032
(9 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10183020 | ASTRAZENECA | Pharmaceutical compositions comprising AZD9291 |
Jan, 2035
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Dec 18, 2027 |
New Indication (I) | Dec 18, 2023 |
Market Authorisation Date: 13 November, 2015
Treatment: Treatment of patients with metastatic epidermal growth factor receptor (egfr) t790m mutation-positive non-small cell lung cancer (nsclc), who have progressed on or after egfr tki therapy; Treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21l858r mutations; Adjuvant therapy after tumor resection in patients with non-small cell lung cancer(nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19deletions or exon 21 l858r mutations
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic